Board Change

RNS Number:1494J
Celsis International PLC
01 March 2005


                           CELSIS INTERNATIONAL PLC

                         Non-Executive Director Change


1 March 2005: Celsis International plc ("Celsis" or the "Company"), the
microbial detection and analytical services company, today announces that Dr
Peter Grant will stand down as non-executive director of the Board with
immediate effect.  Dr Grant leaves Celsis to pursue his career as Operations
Director of the recently floated Biofusion plc.  He has served as non-executive
director of the Company since May 2002, prior to this he was an executive
director since Celsis floated on the London Stock Exchange in 1993.


Jack Rowell, Non-Executive Chairman of Celsis, commented:


"We are extremely grateful to Peter for the significant contribution he has made
to the formation and development of Celsis, both in his capacity of executive
and non-executive director, over the last 12 years.  As a founding director of
Celsis, Dr Grant was responsible for developing the technology base from concept
to product and was instrumental in growing Celsis into the successful company
that it is today.  On behalf of the Board we wish Peter well in his future
career and thank him for his commitment to Celsis."


Enquiries:

Celsis International plc                                      Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Financial Dynamics                                            Tel: [phone]
Ben Atwell
Lucy Briggs

Notes to editors


Celsis International plc

Celsis International plc is a microbial detection and analytical services
company operating through two divisions, the Product Group and the Laboratory
Group.


Using its proprietary enzyme technology, the Product Group is the world leader
in the provision of diagnostic systems for the rapid detection of microbial
contamination.  It works in close collaboration with many of the world's leading
pharmaceutical, personal care and beverage companies, ensuring the safety and
quality of products bound for consumers.  The Laboratory Group provides
outsourced analytical testing services to pharmaceutical companies to ensure the
stability and chemical composition of their products.


In addition to ensuring product quality and safety for consumers, both divisions
have the capacity to deliver substantial cost savings to Celsis' customers.  By
reducing the time it takes to test and release raw materials and finished goods
to the market place, Celsis' products facilitate increased manufacturing
productivity and improved supply chain management.


Celsis International plc is listed on the London Stock Exchange (CEL.L).
Further information can be found on the Company's website at www.celsis.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAPKFKPOBKDNBB